Clinical Trial Update: Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial update reports safety and immune response data for the dengue virus vaccine rDEN3-3'Ddelta30 in healthy adults; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• rDEN3-3'Ddelta30 Dengue virus vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED